MXPA03006321A - Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa. - Google Patents
Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa.Info
- Publication number
- MXPA03006321A MXPA03006321A MXPA03006321A MXPA03006321A MXPA03006321A MX PA03006321 A MXPA03006321 A MX PA03006321A MX PA03006321 A MXPA03006321 A MX PA03006321A MX PA03006321 A MXPA03006321 A MX PA03006321A MX PA03006321 A MXPA03006321 A MX PA03006321A
- Authority
- MX
- Mexico
- Prior art keywords
- oxidase
- antagonists
- treatment
- amino acid
- cns disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26188301P | 2001-01-16 | 2001-01-16 | |
| US30544501P | 2001-07-13 | 2001-07-13 | |
| US34521101P | 2001-10-22 | 2001-10-22 | |
| US33388101P | 2001-11-19 | 2001-11-19 | |
| PCT/IB2002/001262 WO2002066672A2 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006321A true MXPA03006321A (es) | 2003-10-06 |
Family
ID=27500728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006321A MXPA03006321A (es) | 2001-01-16 | 2002-01-15 | Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1412515A2 (https=) |
| JP (1) | JP2004537275A (https=) |
| KR (1) | KR20030066813A (https=) |
| CN (1) | CN1568370A (https=) |
| AU (1) | AU2002247939B2 (https=) |
| BR (1) | BR0206495A (https=) |
| CA (1) | CA2433866A1 (https=) |
| EA (1) | EA006654B1 (https=) |
| IL (1) | IL156865A0 (https=) |
| MX (1) | MXPA03006321A (https=) |
| WO (1) | WO2002066672A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60228954D1 (en) | 2001-05-03 | 2008-10-30 | Galileo Lab Inc | Pyruvatderivate |
| WO2003070743A1 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| AU2002339696A1 (en) * | 2001-12-03 | 2003-06-17 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| US20060234221A1 (en) * | 2001-12-12 | 2006-10-19 | Genset S.A. | Biallelic markers of d-amino acid oxidase and uses thereof |
| GB0223424D0 (en) * | 2002-10-09 | 2002-11-13 | Imp College Innovations Ltd | Disease-associated gene |
| JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| JP5367377B2 (ja) * | 2006-01-09 | 2013-12-11 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患治療のためのランチオニン関連化合物 |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| GB2456390A (en) * | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| CN102292094B (zh) | 2009-01-20 | 2013-08-14 | 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 | 增强神经药方疗效的山梨酸与苯甲酸及其衍生物 |
| JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤 |
| WO2012135119A1 (en) * | 2011-03-25 | 2012-10-04 | Genomind, Llc | Biomarker-based detection and treatment of neurodegenerative depression |
| AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| RU2765625C2 (ru) | 2016-06-13 | 2022-02-01 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| CN108504752B (zh) * | 2018-06-26 | 2021-05-11 | 华中农业大学 | 一种与母猪繁殖性状关联的分子标记及应用 |
| CN111909907B (zh) * | 2020-07-08 | 2022-05-24 | 浙江工业大学 | 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| EP1165836A2 (en) * | 1999-03-30 | 2002-01-02 | Genset | Schizophrenia associated genes, proteins and biallelic markers |
| WO2001009118A2 (en) * | 1999-07-29 | 2001-02-08 | Patrick T Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
-
2002
- 2002-01-15 EP EP02717019A patent/EP1412515A2/en not_active Withdrawn
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Ceased
- 2002-01-15 CA CA002433866A patent/CA2433866A1/en not_active Abandoned
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002247939B9 (en) | 2002-09-04 |
| JP2004537275A (ja) | 2004-12-16 |
| EA200300807A1 (ru) | 2004-08-26 |
| CN1568370A (zh) | 2005-01-19 |
| EP1412515A2 (en) | 2004-04-28 |
| BR0206495A (pt) | 2006-01-24 |
| WO2002066672A2 (en) | 2002-08-29 |
| IL156865A0 (en) | 2004-02-08 |
| WO2002066672A3 (en) | 2004-02-26 |
| KR20030066813A (ko) | 2003-08-09 |
| CA2433866A1 (en) | 2002-08-29 |
| EA006654B1 (ru) | 2006-02-24 |
| AU2002247939B2 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03006321A (es) | Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa. | |
| AU2002339696A8 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors | |
| MXPA03007960A (es) | Compuestos y metodos para el tratamiento de desordenes urogenitales. | |
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| ZA200204020B (en) | Use of anti-CTLA-4-antibodies. | |
| MXPA03007816A (es) | Calzoncillo desechable y metodo para proporcionar el mismo. | |
| ZA200306171B (en) | (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes. | |
| ZA200306232B (en) | Treatment involving DKK-1 or antagonists thereof. | |
| AU4541101A (en) | Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders | |
| EP1383865A4 (en) | METHOD FOR THE PRODUCTION OF TYROSIN, Cinnamic Acid and Para-Hydroxycinnamic Acid | |
| MXPA03007130A (es) | Conjugados de peg de hgf-nk4. | |
| WO2003010291A3 (en) | Treatment of immune disorders and b cell disorders | |
| AU9527001A (en) | Treatment of T cell disorders | |
| ZA200208247B (en) | Treatment of mixed metal oxide catalyst. | |
| ZA200306327B (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid. | |
| GB0128674D0 (en) | Treatment of sleep disorders and the like | |
| DE60036723D1 (de) | Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen | |
| ZA200407412B (en) | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders. | |
| IL161741A0 (en) | Methods of reversing and preventingcardiovascular pathologies | |
| GB9922710D0 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis | |
| GB0109091D0 (en) | Hypertension treatment and assay | |
| EP1315499A4 (en) | COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES | |
| NZ528896A (en) | Treatment of ADHD | |
| AP2004002980A0 (en) | The treatment of lipodystrophy. | |
| AU3582101A (en) | The treatment of functional gastrointestinal disorders |